ArticleBioinformation2025
Validation of the BARD scoring system for fibrosis detection in nonalcoholic fatty liver disease.
Article in Bioinformation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The diagnostic performance of the BARD scoring system in detecting significant fibrosis (≥F2) among Bangladeshi patients with biopsy-proven NAFLD is of interest. A cross-sectional study was conducted on 40 adult NAFLD patients at Bangladesh Medical University, Dhaka. Liver fibrosis was staged histologically from biopsy specimens. The BARD score was calculated for each patient and its diagnostic accuracy was evaluated using sensitivity, specificity, predictive values and ROC curve analysis. Clinical and biochemical predictors of fibrosis were also assessed. Among the cohort, 45% had significant fibrosis (F2-F4). The BARD score demonstrated a sensitivity of 83.3%, specificity of 86.4%, positive predictive value of 83.3%, negative predictive value of 86.4% and an AUROC of 0.908 (p < 0.001). A strong positive correlation was observed between BARD score and fibrosis stage (r = 0.736). Multivariate analysis identified BMI ≥28 kg/m
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.